On the stock market since 2022, it operates in the world of health and science. It has 1,300 employees. Now — the numbers.
This is an established company with proven profits.
Average growth of 25% a year over the last 4 years. Red columns mark years that ended in a loss.
The gap is $183.7M. In times of high interest rates, a gap like that can squeeze a company.
The stock trades 38% below its peak. The market has trimmed its expectations for the company.
Over the last 3 years, sales grew about 15% a year on average.
The average analyst price target is $42.00 — 1,416% above today’s price.
The company’s market value is 47 times its annual profit. Even a small disappointment could hit the price hard.
On our five-subject report card, VIMGF sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: VIMGF is an established business that has proven its profits for years. The real debate isn’t the quality of the business — it’s whether the price paid for the stock is too high.